SOURCE: Stem Cell Therapy International, Inc.

July 20, 2006 09:15 ET

Stem Cell Therapy International Names Lixian (John) Jiang, Chief Operating Officer, China Division

TAMPA, FL -- (MARKET WIRE) -- July 20, 2006 -- Stem Cell Therapy International, Inc. (PINKSHEETS: SCII), a company in the field of regenerative medicine providing research, development and the treatment of patients with stem cell transplantation therapy, today appointed Lixian Jiang (pronounced "Leechan Geeyang") chief operating officer of the company's newly created China Division.

Mr. Lixian (John) Jiang will supervise the China Division, which will be located in Beijing. In addition to coordination with Chinese hospitals that will perform the cell transplantation therapy, he will oversee the establishment of a cryo-preservation bank for the stem cell biological solutions and management of SCTI's business operations in China, Jiang will act as the company's legal advisor for SCTI's patent applications in China. He will report to the Board of Directors and to Calvin Cao, chairman and chief executive officer of Stem Cell Therapy International.

A member of the China Bar Association as well as a licensed agent of the U.S. Patent and Trademark Office, Jiang expects to receive his PhD in Medical Science from the University of South Florida next month. He has a degree in medical science from the Academy of Military Medical Science in China as well having researched and published sixty papers and abstracts on stem cell transplantation and medical science in the U.S. and China.

Calvin Cao said, "We are very pleased to bring John on board, his background in science and law matches the needs of SCTI. As stem cell transplantation treatments are a well-established, well-recognized branch of medicine in China, he is the ideal person to work for SCTI to set up its operations in China, so that we can bring patients from other parts of the world there for stem cell treatment."

"We expect to travel to Beijing later this week to begin the process of setting up operations there," Mr. Cao said.

Before joining SCTI, Jiang worked as a patent agent specializing in intellectual property law for a U.S. company, Cedar Patent, LLC, Tampa, FL from December 2003 to June 2006. At this firm, he drafted patent applications and monitored their processing by the U.S. Patent Office. Prior to that he worked as a patent, trademark and tax attorney for Chinese law firms in Shanghai and Beijing.

As a scientist, Jiang has worked as a research assistant in the Neurosurgery Department of the University of South Florida in the field of stem cell culture, cryo-preservation and transplantation. In China, he was a postdoctoral fellow at the Trauma Center of the 304th Hospital in Beijing, working with severely burned patients. He also was a research assistant at the Academy of Military Medical Science in Beijing while he was pursuing his Master's Degree.

Stem cell transplantation therapy is a field of regenerative medicine, which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. This therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for expensive and potentially dangerous immunosuppression drug therapy. These new techniques are being applied to finding a cure and for the treatment of a wide range of human disorders, including many neurological diseases.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to promote stem cell research. Since that time, four other states New Jersey, Connecticut, Illinois and Wisconsin, have allocated significant funds for stem cell research. For additional information on SCTI's research and treatment programs please visit our website @ www.scticorp.com.

About Stem Cell Therapy International, Inc. (SCTI)

Stem Cell Therapy International, Inc. is engaged in the field of research and development of regenerative medicine. SCTI manufactures stem cell biological solutions that are currently being used in the treatment of patients suffering from degenerative disorders of the human body such as MS, stroke, diabetes, Alzheimer's, Parkinson's Disease, ALS, leukemia, muscular dystrophy, arthritis, spinal cord injuries, brain injury, heart disease, liver and retinal disease as well as certain types of cancer and can be used to alleviate the side effects of chemotherapy. The Company has filed a provisional patent describing the successful process in the treatment of severe burns with Cryopreserved human stem cells. This technique will be used in other types of cosmetic applications such as the prevention of scar tissue after surgery and for skin rejuvenation therapy. SCTI has established agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI intends to provide these biological solutions containing stem cell products in the United States as well to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Its products, which are available now, include various stem cell biological solutions containing (human stem cells), low-molecular proteins, nutrients and human growth factor hormones.

Forward-Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

Contact Information

  • For more information, please contact:
    Stem Cell Therapy International
    Calvin C. Cao
    Chairman and CEO
    Stem Cell Therapy International
    E: calvin@scticorp.com

    Investor Relations
    Arun Chakraborty
    Investor Relations
    Stern & Co.
    T: 212-888-0044
    E: achakrab@sternco.com

    Media Relations
    Stan Froelich
    VP, Media Relations
    Stern & Co.
    T: 212-888-0044
    E: sfroelich@sternco.com

    Stem Cell Therapy International
    Peter K. Sidorenko
    Chief Operating Officer
    Stem Cell Therapy International
    E: peter@scticorp.com